Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for
participation in this study.

- Current participant or willingness to participate in the CFF patient registry
database

- ≥ 6 years of age

- Subject has CF as diagnosed by one of the following

- Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis
test, or

- Two well-characterized genetic mutations in the CFTR gene, or

- Abnormal nasal potential difference (NPD) AND accompanying clinical
characteristics consistent with CF. For subjects who lack documentation of
either a positive sweat chloride test or an abnormal NPD, and who have only one
well-characterized genetic mutation of the CFTR gene, the diagnosis of CF is
determined by the Investigator.

- FEV1 ≥ 25% predicted and ≤ 90% predicted.

- ≥ 2 lower respiratory tract cultures positive for PA with results documented in the
subject's medical history.

- Subject must be able to provide written informed consent/assent prior to any study
related procedure; parent/guardian must be able to give written informed consent as
necessary prior to any study related procedure.

Exclusion Criteria:

Subjects who meet the following exclusion criterion are not to be enrolled in this study.

• Any serious active medical or psychiatric illness that, in the opinion of the
Investigator, would interfere with subject assessment.